
Martin and Harris Laboratories Unlisted Share Price
Martin and Harris Laboratories Limited
- CIN
- U24239HR1993PLC033630
- ISIN
- INE03VV01015
- Incorporated
- 22 Jul 1993
- Registered state
- Haryana
Key valuation
- Market cap
- ₹358 Cr
- P/E
- 5.4x
- Debt / equity
- 0.0x
- Shares outstanding
- 40,00,000
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Price history
Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.
About Martin and Harris Laboratories
Martin and Harris Laboratories Limited is a Gurugram-based pharmaceutical and botanical products company that is part of the Apeejay Surrendra Group, one of India's older business groups. It was incorporated in the 1990s.
Alongside its pharmaceutical business, the company holds a sizeable investment portfolio of mutual funds and listed and unlisted shares, which accounts for much of its value.
Martin and Harris reported revenue of ₹107 crore and a net profit of ₹66 crore in FY2025, with a net worth of ₹707 crore.
Key highlights
- Incorporated in 1996
Financial snapshot
FY2025
- Revenue FY2025
- ₹107.43 Cr
- EBITDA
- ₹88.97 Cr
- PAT
- ₹66.30 Cr
- Net worth
- ₹707.06 Cr
- Total debt
- ₹13.00 Cr
- Cash & equivalents
- —
- Operating cash flow
- ₹273.56 Cr
- EPS
- ₹166
Management & board
- HSSince 2017
Harnam Singh Thakur
Nodal Officer, Director
- NUSince 2022
Nasim Uddin
Director
- ACSince 2023
Ashok Chandra Sen
Director
- VMSince 2022
Vivek Manohar Padgaonkar
Director
Reported financials · FY2021–FY2025
Figures in ₹ crore unless stated.
| Particulars | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY | CAGR |
|---|---|---|---|---|---|---|---|
| Profit & loss | |||||||
| Revenue from operationsYoY -26.5%CAGR -10.5% | 168 | 186 | 205 | 146 | 107 | -26.5% | -10.5% |
| Other incomeYoY +27.7%CAGR -28.5% | 168 | 26 | 24 | 34 | 44 | +27.7% | -28.5% |
| Total expensesYoY -16.1%CAGR -2.1% | 115 | 119 | 137 | 125 | 105 | -16.1% | -2.1% |
| EBITDAYoY +47.3%CAGR -20.7% | 225 | 97 | 96 | 60 | 89 | +47.3% | -20.7% |
| Depreciation & amortisationYoY +5.7%CAGR +11.0% | 3 | 3 | 4 | 5 | 5 | +5.7% | +11.0% |
| EBITYoY +50.7%CAGR -21.5% | 221 | 94 | 92 | 56 | 84 | +50.7% | -21.5% |
| Finance costYoY +86.7%CAGR +53.8% | 0 | 0 | 0 | 1 | 1 | +86.7% | +53.8% |
| Profit before taxYoY +50.4%CAGR -21.7% | 221 | 93 | 92 | 55 | 83 | +50.4% | -21.7% |
| Tax expenseYoY +9.5%CAGR -22.2% | 44 | 23 | 24 | 15 | 16 | +9.5% | -22.2% |
| Profit after taxYoY +64.1%CAGR -21.8% | 177 | 70 | 68 | 40 | 66 | +64.1% | -21.8% |
| Earnings per shareYoY +64.1%CAGR -21.8% | ₹442 | ₹176 | ₹170 | ₹101 | ₹166 | +64.1% | -21.8% |
| Balance sheet | |||||||
| Net worthYoY +11.9%CAGR +12.2% | 446 | — | 593 | 632 | 707 | +11.9% | +12.2% |
| Total debtYoY +66.7%CAGR +30.4% | 5 | 5 | 4 | 8 | 13 | +66.7% | +30.4% |
| Current liabilitiesYoY -87.8%CAGR -34.5% | 189 | 215 | 249 | 285 | 35 | -87.8% | -34.5% |
| Current assetsYoY +48.8%CAGR +22.6% | 280 | 321 | 370 | 425 | 633 | +48.8% | +22.6% |
| Total assetsYoY +13.1%CAGR +12.9% | 461 | 543 | 615 | 662 | 749 | +13.1% | +12.9% |
| Cash flow | |||||||
| Operating activitiesYoY +368.4%CAGR +64.0% | 38 | 44 | 51 | 58 | 274 | +368.4% | +64.0% |
| Investing activities | -19 | -22 | -25 | -28 | -272 | — | — |
| Financing activities | -17 | -20 | -23 | -27 | 3 | — | — |
| Free cash flowYoY +476.8%CAGR +72.0% | 30 | 34 | 40 | 45 | 261 | +476.8% | +72.0% |
| Net change in cashYoY +34.3%CAGR +22.3% | 2 | 2 | 3 | 4 | 5 | +34.3% | +22.3% |
YoY compares the latest year with the one before it. CAGR runs from the oldest reported year to the latest. A dash means the year is missing, or the starting figure is zero or negative, so a percentage would mislead.
Margins, returns, liquidity, leverage and every other ratio from these figures: see RatiosRevenue, EBITDA and PAT
₹ crore. A year with no reported figure is left out rather than drawn as zero.
- Revenue
- EBITDA
- PAT
Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.
Valuation multiples
What the indicative price pays for the latest year's earnings, book and cash. On FY2025 figures and the ₹895 indicative price.
- Market cap
- ₹358 Cr
- Enterprise value
- ₹371 Cr
- Price / earnings (P/E)
- 5.40x
- Price / book (P/B)
- 0.51x
- Price / sales (P/S)
- 3.33x
- Price / operating cash flow
- 1.31x
- EV / EBITDA
- 4.17x
- EV / EBIT
- 4.41x
- EV / sales
- 3.45x
- Earnings yield
- 18.5%
- Free cash flow yield
- 72.8%
How these are worked out
- Market cap
- Indicative price × shares outstanding
- Enterprise value
- Market cap + debt − cash
- Price / earnings (P/E)
- Market cap ÷ PAT (profitable years only)
- Price / book (P/B)
- Market cap ÷ net worth
- Price / sales (P/S)
- Market cap ÷ revenue from operations
- Price / operating cash flow
- Market cap ÷ cash from operating activities
- EV / EBITDA
- Enterprise value ÷ EBITDA
- EV / EBIT
- Enterprise value ÷ (EBITDA − depreciation)
- EV / sales
- Enterprise value ÷ revenue from operations
- Earnings yield
- PAT ÷ market cap
- Free cash flow yield
- (Operating cash flow − capex) ÷ market cap
IPO / listing status
The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.
Research & news
Information currently unavailable
Nothing has been published on Martin and Harris Laboratories yet. Research, news and articles tagged with it will appear here when they are.
Documents
Private documents are shown locked and are released to verified clients on request.
Martin and Harris Laboratories unlisted shares: FAQs
What is the Martin and Harris Laboratories unlisted share price today?
The indicative price of Martin and Harris Laboratories Limited shares is ₹895 per share, as of 17 Nov 2026. Unlisted shares have no exchange price: this figure reflects recent off-market deals and can differ from the price on a particular trade. The price history on this page shows how it has moved.
How can I buy Martin and Harris Laboratories unlisted shares?
Raise a buy enquiry on this page with the number of shares you want. Our desk confirms availability and the price, you pay from a bank account in your own name, and the shares are transferred to your demat account. You need a PAN and a demat account with any depository participant.
How can I sell Martin and Harris Laboratories shares?
Raise a sell enquiry with the number of shares you hold in demat. Once the price is agreed, you transfer the shares from your demat account and the money is paid to a bank account in your name.
Is Martin and Harris Laboratories planning an IPO?
Martin and Harris Laboratories Limited is currently at the "Pre-IPO" stage. No IPO date has been announced. A listing depends on the company and on regulatory approval.
What are Martin and Harris Laboratories's revenue and profit?
In FY25, Martin and Harris Laboratories Limited reported revenue of ₹107 Cr and a profit of ₹66 Cr, with a net worth of ₹707 Cr. The Financials section has the full statements for every year we hold.
Is it legal to buy unlisted shares in India?
Yes. Shares of unlisted public companies can be bought and sold off-market and transferred between demat accounts. They carry more risk than listed shares: prices are not set on an exchange, it can take time to find a buyer, and a listing is never guaranteed.
Is there a lock-in on Martin and Harris Laboratories shares after the IPO?
SEBI rules lock in shares held before an IPO for a period after listing, currently six months from allotment for most investors in a mainboard IPO. Shares bought now in the unlisted market would usually be covered by this lock-in.
How are gains on Martin and Harris Laboratories unlisted shares taxed?
Gains on unlisted shares held for more than 24 months are long-term capital gains; held for less, they are short-term and taxed at your slab rate. Check the current rates with a tax adviser before you sell.

